Tag Archives: manufacturing

National Cancer Institute supports next-generation Austrian HPV vaccine

The National Cancer Institute (NCI) of the US National Institutes of Health (NIH) is supporting further clinical development of a new, improved, next-generation HPV vaccine. The vaccine was developed by a team led by Reinhard Kirnbauer from the Division of Immunodermatology at the MedUni Vienna in collaboration with Christina Schellenbacher and support from the Austrian Science Fund (FWF) and Vienna Science and Technology Fund (WWTF). The new vaccine had already demonstrated its excellent efficacy in a pre-clinical study in 2013…

Advances in nanotechnology’s fight against cancer

A new research review co-authored by a UCLA professor provides one of the most comprehensive assessments to date of research on nanomedicine-based approaches to treating cancer and offers insight into how researchers can best position nanomedicine-based cancer treatments for FDA approval. …

Unreliable commercial lab kits may be hindering fight against cancer

A doctor’s ability to test for cancer in its earlier stages often determines a patient’s chances of survival. Pancreatic ductal adenocarcinoma (PDAC) is a grim example of this. The majority of patients live only 3 to 18 months, because current diagnosis methods usually can’t detect PDAC until it is too advanced to respond to treatment. Testing for the right biomarkers — biological molecules whose presence indicates a condition or disease — could be instrumental in the early detection of cancers like PDAC…

Learning from a virus: Keeping genes under wraps

The discoveries improve the chances of developing more targeted therapies in place of existing drugs, which do not always work or come with side effects. Experts estimate that 60 to 90 percent of the world’s population carry the human cytomegalovirus, or CMV, which is one of the eight herpes viruses that infect humans…

Inexpensive, accurate way to detect prostate cancer: At-home urine tests

After more than a decade of work, UC Irvine chemists have created a way to clearly identify clinically usable markers for prostate cancer in urine, meaning that the disease could be detected far sooner, with greater accuracy and at dramatically lower cost. The same technology could potentially be used for bladder and multiple myeloma cancers, which also shed identifiable markers in urine. "Our goal is a device the size of a home pregnancy test priced around $10…